Centrient Pharmaceuticals

Sustainability Report and Carbon Intensity Rankings

Is Centrient Pharmaceuticals doing their part?

Their DitchCarbon score is 66

Centrient Pharmaceuticals has a DitchCarbon Score of 66, indicating a moderate level of sustainability in their operations. This score reflects the company’s efforts to manage its carbon intensity, suggesting they are taking steps to reduce greenhouse gas emissions. A higher score would denote even greater success in lowering carbon intensity and enhancing sustainability practices.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

Centrient Pharmaceuticals is part of the industrial manufacturing sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Medium

High

Very high

Centrient Pharmaceuticals is located in the Netherlands, which has a very low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing the carbon footprint associated with their operations.

Unlock 30+ emissions intelligence data points

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

Unlock 30+ emissions data points on Centrient Pharmaceuticals

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

24.71%

...this company is doing 24.71% better in emissions than the industry average.

Centrient Pharmaceuticals, headquartered in Rotterdam, Netherlands, was founded in 1869 and operates within the industrial manufacturing sector. As a global leader in sustainable antibiotics, next-generation statins, and anti-fungals, the company specializes in developing, producing, and selling intermediates, active pharmaceutical ingredients, and drug products. With a worldwide presence, including manufacturing sites and sales offices across China, India, Egypt, Spain, the USA, and Mexico, Centrient Pharmaceuticals is wholly owned by the global investment firm Bain Capital.

Compare Centrient Pharmaceuticals with other companies in the same industry –>

emission intelligence's platform recommendations for Centrient Pharmaceuticals

Centrient Pharmaceuticals could potentially reduce their emissions by 20% by transitioning to renewable electricity sources, such as purchasing renewable energy certificates or engaging in direct power purchase agreements.

Good news, Centrient Pharmaceuticals has embraced SBTi commitments

Centrient Pharmaceuticals has pledged to reduce its carbon emissions in line with the Science Based Targets initiative. This commitment involves aligning their business operations with the goal of limiting global warming and pursuing sustainable practices.

Participating

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.

Other company reports in this industry

Looking for a specific company?

Search our company directory or contact us for custom data requests.

Centrient Pharmaceuticals

Sustainability Report and Carbon Intensity Rankings

Is Centrient Pharmaceuticals doing their part?

Their DitchCarbon score is 66

Industry emissions intensity

Very low

Low

Medium

High

Very high

Location emissions intensity

Very low

Low

Medium

High

Very high

Unlock 30+ emissions intelligence data points

Unlock 30+ emissions data points on Centrient Pharmaceuticals

...this company is doing 24.71% better in emissions than the industry average.

emission intelligence's platform recommendations for Centrient Pharmaceuticals

Good news, Centrient Pharmaceuticals has embraced SBTi commitments

Claim this profile

Our methodology

Other company reports in this industry

Looking for a specific company?

Quicklinks

Resources

Get in touch